Written in
Featured research from recent issues of Blood
PAPER SPOTLIGHT
Isatuximab Plus Lenalidomide and
Dexamethasone Active in Relapsed/
Refractory Multiple Myeloma
Treatment with the investiga-
tional anti-CD38 monoclonal
antibody isatuximab (in com-
bination with lenalidomide and
dexamethasone) led to an overall
response rate (ORR) of 51 percent
in a phase Ib study of patients
with relapsed/refractory multiple
myeloma (MM). The results,
published in Blood, suggest that
“potent, synergistic pro-immune
activity can be achieved by the
addition of an [immunomodu-
latory therapy] to anti-CD38
therapy across the spectrum of
patients with relapsed/refractory
MM … especially in patients who
have limited treatment options,”
wrote Thomas Martin, MD, from
the Division of Hematology/
Oncology at the University of
California, San Francisco, and
co-authors.
Adult patients with relapsed/
refractory MM were eligible if they
had adequate blood counts, mea-
surable disease, and an abnormal
serum free light chain ratio (<0.26
or >1.65) or biopsy-proven plasma-
cytoma. Patients were excluded if